Marker Therapeutics, Inc. (MRKR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US57055L2060
Marker Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 3.55 m USD |
| Operating income | -12.89 m USD |
| EBIT | -12.77 m USD |
| Net income | -12.16 m USD |
| Diluted EPS – continuing operations | -0.79 USD |
Full history since 1999, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
More stocks
- Security Midwest Bancorp, Inc. (SBMW)
- American Strategic Investment Co. (NYC)
- FIREFLY NEUROSCIENCE, INC. (AIFF)
- Creative Media & Community Trust Corp (CMCT)
- Citius Pharmaceuticals, Inc. (CTXR)
- NextTrip, Inc. (NTRP)
- Local Bounti Corporation/DE (LOCL)
- QUOTEMEDIA INC (QMCI)
- ARTS WAY MANUFACTURING CO INC (ARTW)
- KEY TRONIC CORP (KTCC)
- T Stamp Inc (IDAI)
- Pacific Sports Exchange Inc. (PSPX)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.